Is there still a role for intermittent androgen deprivation therapy for prostate cancer?—Yes.
Intermittent androgen deprivation (IAD) therapy was first described in mid 1980s in a small pilot study of men with symptomatic, metastatic prostate cancer.1 Men underwent androgen deprivation therapy (ADT) with diethylstilbestrol until symptoms resolved, at which time therapy was withheld until symptomatic progression. The authors1 observed that sexual function returned in 9 of 10 patients who had normal erectile function at baseline. The conclusion was that IAD could adequately palliate symptomatic men and, at the same time, result in improved quality of life (QOL) by allowing return of sexual function in the majority with normal function at baseline.
Klotz L, Higano CS. Intermittent Androgen Deprivation Therapy—An Important Treatment Option for Prostate Cancer. JAMA Oncol. 2016;2(12):1531–1532. doi:10.1001/jamaoncol.2016.3138
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.